



Universiteit
Leiden
The Netherlands

Decisional needs among patients and physicians in the treatment of chronic myeloid leukaemia: a qualitative analysis in the Netherlands

Mingels, S.; Cloots, M.J.J.; Smit, Y.; Blijlevens, N.M.A.; Posthuma, E.F.M.; Dekker, A.L.A.J.; ... ; Kromkamp, C.C.G.

Citation

Mingels, S., Cloots, M. J. J., Smit, Y., Blijlevens, N. M. A., Posthuma, E. F. M., Dekker, A. L. A. J., ... Kromkamp, C. C. G. (2026). Decisional needs among patients and physicians in the treatment of chronic myeloid leukaemia: a qualitative analysis in the Netherlands. *Bmj Open*, 16(1). doi:10.1136/bmjopen-2025-112705

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/4298972>

Note: To cite this publication please use the final published version (if applicable).

BMJ Open Decisional needs among patients and physicians in the treatment of chronic myeloid leukaemia: a qualitative analysis in the Netherlands

Simone Mingels ^{1,2}, Manon J J Cloots ^{3,4}, Yolba Smit,⁵ Nicole M A Blijlevens,⁵ Eduard F M Posthuma,^{6,7} Andre L A J Dekker,^{1,2} Rianne R R Fijten,^{1,2} Esri Wener,⁸ Corien C G Kromkamp⁹

To cite: Mingels S, Cloots MJJ, Smit Y, *et al.* Decisional needs among patients and physicians in the treatment of chronic myeloid leukaemia: a qualitative analysis in the Netherlands. *BMJ Open* 2026;**16**:e112705. doi:10.1136/bmjopen-2025-112705

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2025-112705>).

Received 21 October 2025
Accepted 04 December 2025



© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group.

For numbered affiliations see end of article.

Correspondence to

Simone Mingels;
simone.mingels@
maastrichtuniversity.nl

ABSTRACT

Objective Treatment advancements in chronic myeloid leukaemia (CML) have made the disease manageable but carry significant risk of side effects. Bridging information gaps between patients and physicians through shared decision-making (SDM) is increasingly favoured, yet understanding treatment complexities remains a challenge. This study sought to identify decisional and informational needs of both patients and physicians in CML care.

Design A qualitative study using semi-structured interviews was conducted to investigate the opinions, attitudes and preferences of both patients with chronic myeloid leukaemia and physicians.

Setting Patients and physicians were recruited through the Dutch CMylife platform, an initiative of haematologists, patients and patient organisations. They were provided with the participant information and invited to participate if interested.

Participants A total of 15 interviews (n=10 patients, n=5 physicians) were conducted between April and October 2023.

Primary and secondary outcome measures A pre-defined interview guide was developed based on the Decisional Needs Assessment questionnaire. Interview transcripts were thematically analysed.

Results Eight themes and 28 sub-themes were observed, highlighting patient needs, treatment choices and informational preferences. Patients emphasised the importance of understanding medication options and side effects, while physicians stressed the necessity of delivering up-to-date and comprehensible information. Almost all participants had experienced professionals making the treatment decision, without patient involvement, especially when initiating treatment. Some patients expressed too little information and missed partnership with professionals at treatment onset. Peer support, decision-making dynamics and the role of caregivers were also significant considerations.

Conclusions Both shared and distinct perspectives on CML treatment decision-making between patients and physicians were revealed, underscoring the complexity of decisional needs in CML management. The findings emphasise the importance of patient-centred care, SDM and tailored communication strategies to optimise patient

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The semi-structured open nature of the interviews allowed for a deep understanding of personal experience and expanding of knowledge on decisional needs.
- ⇒ The recruitment of active patients through the CMylife platform and the relatively small sample size may not have fully captured the experiences of all patients through the possible introduction of selection bias in the study.
- ⇒ Inclusion of patients and physicians from multiple centres across the Netherlands may enhance the generalisability of findings to the broader population.

outcomes and satisfaction. Improved communication and evidence-based decision-making tools can significantly impact patient well-being. Further research and interventions are necessary to address the challenges in decision-making processes in CML care.

INTRODUCTION

Chronic myeloid leukaemia (CML) is a type of blood cancer characterised by the uncontrolled growth of myeloid cells in the bone marrow.¹ This abnormal growth is caused by a genetic mutation that leads to the formation of a fusion gene, known as BCR::ABL1.^{1,2} To block the excessive growth and division of myeloid cells, treatment with tyrosine kinase inhibitors (TKIs) is standard care.² TKIs have transformed CML from a life-threatening condition to a usually manageable chronic malignant disease with a life expectancy almost equivalent to the normal population, enabling patients to lead relatively normal lives with ongoing treatment and regular monitoring.^{3–5} However, these treatments carry significant risks of severe side effects, particularly cardiac adverse events.⁶ Monitoring and, if necessary, switching medication are crucial for patients with pre-existing

cardiac conditions, predispositions towards cardiac disease or those experiencing severe side effects.⁷ Medication discontinuation may be necessary for those intolerant or resistant to TKI treatment.⁸ These decisions are generally initiated by the treating physician, guided by clinical guidelines and standard practice.^{29 10}

Patients with CML often have different goals and concerns compared with their physicians, including a greater need for information and understanding about potential side effects.¹¹ This highlights the need for improved communication and shared decision-making (SDM) practices in CML care. SDM empowers patients by granting them greater autonomy in their treatment decisions.¹² It fosters patient engagement by providing them with comprehensive information to assess the benefits and risks of various treatment options, thereby enhancing their understanding of potential side effects and enabling their inclusion in the monitoring process.^{12 13} Navigating SDM in cancer care can be challenging due to the need to fully understand the benefits, harms and uncertainties of treatment.¹⁴ Additionally, certain systemic cultural constraints within clinical practice may hinder the effective implementation of SDM.¹⁵ The literature shows that patients increasingly prefer active involvement in healthcare decisions, though this varies depending on the specific decision and patient characteristics.¹⁶ To facilitate the process of SDM in the selection of the most suitable treatment for patients with CML, this study sought to identify decisional and informational needs of both patients and physicians in CML care.

METHODS

Study design

A qualitative study with semi-structured interviews was used to investigate the opinions, attitudes and preferences of both patients with chronic myeloid leukaemia and physicians. This allowed for exploration of patterns and themes while still permitting comparisons between respondents. The Standards for Reporting Qualitative Research guidelines were used.¹⁷ A pre-defined interview guide based on the Decisional Needs Assessment questionnaire¹⁸ was used uniformly across all interviews, as it contains pre-defined broad questions that trigger conversation. Distinct versions were tailored for patients with chronic myeloid leukaemia to ascertain their decision-making needs and for healthcare practitioners to identify areas for enhancing patient support during decision-making (see online supplemental files 1,2). Each version included broad questions that triggered conversation regarding SDM.

Researcher characteristics and reflexivity

SM was a first-year PhD candidate in the Clinical Data Science department at Maastricht University with 2 years' experience in qualitative analysis; her research focuses on communication about AI and patient decision aids. MJJC was a third-year PhD candidate in a research group

developing decision aids for inflammatory bowel disease. RRRF is an assistant professor in Clinical Data Science and supervisor of SM and MJJC. Her group focuses on AI development and implementation, patient decision aid development and SDM. None of the researchers had a treatment relationship with participants. We anticipated that our backgrounds in clinical data science, AI, decision-aid development and SDM could orient questioning and interpretation toward communication, information needs and decision support.

Study participants

At the start of the study, participants were recruited using convenience sampling from two populations, as recruitment was facilitated through collaboration with a third-party intermediary. Initially, patients were enlisted through contact with the Dutch CMyLife network,¹⁹ an initiative of Radboud university medical centre in which haematologists, patients and patient organisations support and improve the quality of care for individuals with a haematological malignancy. Patients from different hospitals across the Netherlands were informed about the study via the CMyLife team and given participant information, consisting of a study rationale and consent form. If interested, patients could provide their contact details for further contact with our research team for participation in the study. Written informed consent was obtained before the interview. Patients were informed about the burden of the intervention and time required to participate in the research. Second, physicians were recruited by the CMyLife team, after which they were contacted by our research team, where they were provided with the participant information and invited to participate if interested. Patients were included in the study if they were of adult age (>18 years) and were previously diagnosed with CML. Physicians were included if they were actively practising medicine within a Dutch hospital and regularly treated patients with CML (at least monthly). Data saturation was concluded when no new emergent themes were detected.

Data collection and analysis

Demographic information of participants was collected at the start of each interview. Interviews were conducted by two researchers (MJJC, RRRF), online via Microsoft Teams or over the phone, based on the digital literacy of the participant. Interviews lasted between 30 and 60 min. Video and/or audio recordings of interviews were transcribed and anonymised. Transcripts were coded using Atlas.ti software for qualitative data analysis (V.23). Two researchers (MJJC, SM) independently generated inductive codes for selections of the transcript relevant to the aim of this research, according to codebook thematic analysis.²⁰ Themes were developed by comparing codes within and across transcripts, clustering related codes and examining patterns and relationships. Theme definitions were iteratively refined through discussions and comparisons. Any disagreements between coders were resolved through discussions with a third researcher (RRRF) to

reach consensus. Any confusion regarding answers of participants was resolved by contacting said participant, asking for clarification. Participants were not asked to provide feedback on the results.

Patient and public involvement

This research was initiated by the CML patient organisation, which raised the research question based on patient-identified needs. Patients and patient representatives were involved in shaping the research aims and contributed to the study design. Identifying topics related to patient preferences in CML care may provide a foundation for supporting patients during decision moments throughout their treatment journey and facilitate SDM. It may even form the basis of the content and format of a decision aid, which can be used to disseminate information to a wider CML community. Participants could opt to receive the study results, which will be shared after publication with those who expressed interest.

RESULTS

General characteristics

A total of 15 interviews were conducted between April and October 2023, consisting of patients (n=10) and physicians (n=5). None of the patients or physicians contacted by the research team were excluded following initial recruitment. The education level is indicated according to the European Qualifications Framework.²¹ Decision moments that emerged during the interviews included the following: starting medication, switching between medication, changing medication dose, pausing medication and stopping medication. All patients experienced more than one decision in their CML disease trajectory, even those with a disease duration of 1 year. The demographic results are summarised in [table 1](#).

A total of eight themes and 28 sub-themes related to treatment decisions and informational needs were identified (see [table 2](#)). Patients and physicians had a different mention of subthemes in their interviews (visualised in online supplemental file 3). The overall decisional needs and example quotes of both patients and physicians are summarised in [table 3](#).

Discussed treatments and side effects

Patients and physicians were asked which medication they received or previously prescribed, along with the conditions influencing these treatment choices. Both groups discussed TKIs such as dasatinib, imatinib and nilotinib. In contrast, asciminib, bosutinib and ponatinib were exclusively discussed by physicians, while one patient referred to tucatinib. Discussions surrounding medication options underscored the adverse effects associated with treatment (see online supplemental file 4). Certain aspects, such as the frequency of intake, were not always consistently recalled by patients, particularly with dasatinib. Some patients were not able to specify their medication while describing the experienced side effects.

Table 1 Summary participant characteristics

	Patients (n=10)	Physicians (n=5)
Sex		
M	5	2
F	5	3
Median age (range)	64 (56–71)	54 (31–60)
Education		
EQF2	1	
EQF4	3	
EQF6	6	
Median disease duration (range)	7 (1–19)	
Discipline		
Internist haematologist		4
Nurse practitioner		1
Decisions discussed		
Starting medication	9	
Switching between medication	7	
Changing medication dose	8	
Pause of medication	3	
Stopping medication	3	

Patients tended to focus on the impact of treatment on daily life and activities, for example, muscle pain or cramps and fatigue/malaise. In contrast, physicians spoke more about strictly physical side effects of the treatments, such as gastrointestinal issues and fluid retention.

Treatment choices

Patients were asked to reflect on what, if any, treatment choices they made during their disease duration, and which role they played in these decisions. Physicians were asked how they make decisions regarding treatment for the patients and what role patients may play in this. All physicians reported the use of guidelines in their decision-making, although patients did not always perceive this consistency. All physicians noted that their selection of medication was partially guided by their individual preferences and experiences with medications.

In agreement with the Dutch guidelines,²² most physicians preferred to initiate treatment with Imatinib, and in compliance, many patients started their treatment with Imatinib. Reasons for this preference included the reasonable safety and limited toxicity, compromising the often-experienced side effects by patients. Several medical indications were mentioned for deviating from the standard medication regimen, such as the desire to become pregnant, risk of cardiovascular problems, diabetes or a mutation. Physicians also indicated that the quality of life and autonomy and motivation of the patient influenced the medication choice. When patients experienced a significant number of side effects, many switched medication, while some adjusted their medication dose, took

Table 2 Emergent themes and subthemes

Theme	Subtheme
TKI side effects	Physical side effects Psychological side effects
TKI choice	Guidelines, indications and preferences Starting medication Switching medication Changing medication dose Pause of medication Stopping medication Quality of life
Decision-making	Decision made by patient Decision made together with patient and physician Decision made by physician
Additional caregivers	Nurse practitioner General practitioner Psychologist Satisfied with treating physician
Informational characteristics	Comorbidities Online information Paper-based information Understandable information Prediction model and personalised information Information provision
Informational content	Medication options Understanding CML
Peer support	Online peer support Real-life peer support
Relatives	Involved relatives Role of relatives

CML, chronic myeloid leukaemia; TKI, tyrosine kinase inhibitor.

a break from their medication or discontinued the medication altogether. Additionally, some patients mentioned several other reasons for switching medication, such as cost-saving measures, mutation, lack of efficacy or elevation of BCR::ABL1. Dosage adjustments were also made based on favourable or unfavourable blood values or cost-saving measures. Discontinuation of medication could result from achieving a good response and disease control.

Physicians rarely indicated that a patient made their treatment choice independently, whereas patients more frequently reported having done so. A majority of the patients and physicians indicated that medication choices were made in collaboration or based on the physician's recommendations. Patients repeatedly emphasised the importance of effective dialogue between themselves and their physicians in decision-making processes. Nearly all patients and all physicians reported that at least one of the treatment decisions was not a collaborative effort, but rather solely determined by the physician. This narrative was predominant with patients at the start of their disease trajectory. On several occasions, this occurred on

the patient's request, due to fear of making the decision or feeling unprepared to choose their medication. Physicians also noted some instances where patients themselves expressed a preference against making their own choice.

Professional caregivers

Patients and physicians were asked about the role that professional caregivers may play to support both groups. Most patients expressed a need to discuss treatment options with their treating physician or nurse practitioner. Physicians acknowledged that nurse practitioners can aid in treatment decision-making, if empathetic and considerate. Only one patient felt the desire to discuss their disease and options with their general practitioner. Furthermore, one patient and one physician suggested that patients could benefit from guidance from a psychologist. Overall, patients were satisfied with their current attending physician.

Informational characteristics

Patients and physicians were asked how disease-related information and information about treatment options can best be fabricated and disseminated, and which conditions they must meet. In addition, both groups were asked about their own experiences with this. Patients outlined several prerequisites that information must meet before dissemination to patients, namely reliability, accessibility and alignment among various informational sources. There was a call for vigilance regarding the privacy implications of certain informational sources, particularly of some online platforms. One physician emphasised the importance of keeping information up to date. Most physicians indicated directing patients to websites, in agreement with most patients who expressed a preference for digital information resources. Some patients also independently sought information online, primarily through patient platforms, although a physician cautioned that consulting online sources may not always be ideal due to the potential risk of encountering misinformation. Some patients expressed a preference for accessing their personal medical records through online hospital systems. Moreover, some patients were offered paper-based informational materials in the form of pamphlets by their physicians. Interestingly, an equal number of patients expressed both a desire and a lack of interest in receiving pamphlets.

Both groups highlighted the need for conveyed information to be comprehensible. All physicians acknowledged the challenge of effectively communicating information to patients. Patients indicated varying preferences as to whether they require training to facilitate communication with healthcare providers or not. Most patients emphasised a desire for personalised risk assessment, including the chance of success of treatment and side effects based on patient characteristics, while others had no interest. Some patients and physicians expressed interest in predictive models for patient care, highlighting the importance of reliability in such models.

Table 3 Decisional needs and example quotes of patients and physicians

Theme	Patients	Physicians	Example quotes
Discussed treatments and side effects	Clear information regarding medication options, their requirements of use and side effects, predominantly focused on their effect on daily life and activities.	Clear information regarding medication options and their side effects, predominantly focused on severe physical side effects.	<i>"Oh yes, I'm a bit old school, so I usually make a choice for the patient. I explain that 'I want this and I want to give you that, for this and this reason'". (physician E)</i>
Treatment choices	Information on the options in treatment continuation regarding switching of medication, adjusting of medication dose, discontinuation of treatment and the consequences of treatment non-adherence.	Consideration of clinical guidelines, medication pricing, medical indications, quality of life, autonomy and motivation and individual preferences and experiences with medications.	<i>"When I mentioned that my complaints remained such that it significantly affected my life and my daily activities, he offered me the option of taking another medication." (patient D)</i>
	Effective dialogue between patients and physicians in decision-making processes.	Collaborative choice between physician and patient, or based on the physician's recommendations.	<i>"That's right, that's the problem. The distance between doctor and patient is just too great. They have to be able to find each other." (patient B)</i>
Professional caregivers	The possibility to discuss treatment options with the treating physician or nurse practitioner in an empathic manner.		<i>"I was then transferred from one hospital to another. And the first thing they ask is: 'How are you actually doing? How do you feel?'. And I thought that was really brilliant." (patient A)</i>
Informational characteristics	Reliable, accessible, comprehensible and consistent information, preferably through online resources, while guaranteeing privacy.	Current information, preferably through online resources, that is reliable and given by the physician.	<i>"And I had already read everything. The moment I knew I had CML, I immediately started looking." (patient B)</i>
	Effective and understandable communication with their healthcare providers.	An effective manner of communicating information to patients.	<i>"Well, armed to the teeth, that's how I always go to the visits with the haematologist. I do feel like I really, well almost, let's say have to develop to her level in order for the conversations to run smoothly. It is, that's a bit of a challenge." (patient G)</i>
	The possibility of personalised information, with or without predictive models, based on individual preference.	The possibility of personalised information, with or without predictive models, while ensuring reliability.	<i>"No, I don't want to know. No, that's the risk, that's the risk. I think that maybe unconsciously to live like that, I would just get scared." (patient H)</i>
Informational content	More input and information at diagnosis regarding treatment selection.	Reassurance during initial phase and not overwhelming patients with disease-related information.	<i>"There was no choice, so you can talk about it, but doesn't make much sense. If you want to survive, you just have to start taking those pills." (patient I)</i>
	Comprehend the advantages and disadvantages associated with different treatment choices, based on individual preference.	Explaining various medication options to patients, including anticipated reactions and possible side effects.	<i>"You try to explain as best as possible what the side effects are, what the current guidelines are, and how much response you expect based on the profile the patient has." (physician A)</i>
	Review information retrospectively.	For patients to understand the nature of the disease.	<i>"The first thing you hear is that you have leukaemia. And you're like, will I still see my kids turn 18? That's the first thing you think. Then you come home, and the initial shock is over, and then you want to ask for information. What is CML?" (patient C)</i>

Continued

Table 3 Continued

Theme	Patients	Physicians	Example quotes
Peer support	Forum/discussion group, both online as well as physical.	Inform patients about forums or peer support contacts, preferably patients with similar treatment expectancies or well-being.	<i>"My experience is that most people who want to participate in discussion groups do so because they have a certain, yes, those people often have slightly more negative experiences than positive ones." (physician D)</i>
Relatives	The involvement of a family member or other significant person in treatment support.		<i>"Especially at the beginning of the treatment process, or if things are not going well, they usually bring someone with them. That is usually either the partner or a child." (physician B)</i>

Furthermore, there is a notable disparity regarding the timing of information provision to patients. Physicians advocated against overwhelming patients with disease-related information during the acute or initial phase post-diagnosis and underscored the significance of reassurance. Moreover, many patients expressed significant anxiety during the period surrounding the diagnosis of CML. Some patients, however, indicated that at the time of diagnosis they had too little engagement in the decision and received too little information.

Informational content

Patients and physicians were asked which disease-related information they think is important to give or receive, and which information they already gave or received previously. All physicians stressed the importance of explaining the various medication options to patients. Most patients expressed a fundamental need to understand the advantages and disadvantages associated with different treatment choices and often expressed a desire to review such information retrospectively. Some physicians also underscore the importance of informing patients about the anticipated reactions and side effects that may occur. According to most physicians, it is also important for patients to understand the nature of the disease itself. However, most patients themselves did not express this need.

Peer support

Patients and physicians were asked about their opinion of support of fellow patients in different settings. Many patients express a need for a discussion group to exchange experiences and interact with others who share similar experiences. Specifically, this includes a preference for online forums, as well as offline alternatives. Most physicians indicate that they inform patients about forums or peer support contacts, with the condition that accessibility remains a priority. However, they do not distinguish between online and in-person contact. Additionally, one physician noted that peer support and discussion groups may not always align with treatment expectations or patient well-being.

Relatives

Patients and physicians were asked about the role that relatives play in the patient's disease journey. Patients typically do not attend consultations with their physician alone. Patients themselves indicate bringing their partner to consultations and mention their involvement in the decision-making processes. Physicians also frequently observed the presence of partners during consultations, alongside (adult) children, parents and caregivers. While typically characterised as taking a supportive role, some individuals also offer advice, and in certain instances, they assume a leadership role.

DISCUSSION

The present study used qualitative methodology to investigate the decisional needs of patients and physicians in management of CML treatment. The findings revealed both commonalities and differences. Patients emphasised the impact of treatment on daily life, whereas physicians focused on physical side effects, although they acknowledged the importance of quality of life and patient autonomy. This reflects earlier work demonstrating a mismatch between patient-reported and physician-reported symptom burden in chronic haematological conditions such as CML, where physicians frequently underestimate the extent to which side effects affect patients' quality of life.^{23 24} Therefore, enhanced communication and SDM are crucial to establish patient involvement in decision-making and adapt information preferences explicitly for each patient encounter.^{11 25}

This study provides insights suggesting that while several medication decisions were subject to SDM, initial decisions were often physician-led. In some cases, this reflected patients' preference to defer responsibility, but others recalled feeling excluded. Prior research has shown that these patients may view the decision-making process more negatively compared with those engaged in collaborative or autonomous decision-making.^{13 26 27}

Patients frequently described seeking additional resources online motivated by the desire for more information on symptoms, prognosis and treatment options. In

addition, they expressed their interest in forums or discussion groups with fellow patients with chronic myeloid leukaemia. Such support groups can offer emotional support and guidance from those sharing similar experiences.^{28 29} Physicians highlighted the importance of patients understanding their disease, while patients stressed the need to understand the advantages and disadvantages of various treatment options. Informed patients often feel more empowered in managing their disease and are more likely to adhere to treatment.²⁹ Tailored information considering content, delivery and timing may address patients' perceived information needs.^{30 31} However, effectively communicating risk information to the public presents a challenge, requiring careful consideration of potential risk overestimations.³²

Physicians advocate against overwhelming patients with extensive disease-related information during the acute or initial phase post diagnosis,¹¹ as excessive information can be confusing and overwhelming, especially in the initial stages of a patient's journey.²⁹ Patients, however, often felt they received insufficient information during this period. Research shows that patient satisfaction is higher when information needs are met early in the cancer journey.³³ Many patients described the time of diagnosis to be stressful and anxious, emphasising the value of revisiting treatment information retrospectively, which is in line with earlier research.³⁴ Remembering detailed medical information is challenging, particularly among older patients and those with poor prognosis or high anxiety levels.^{35–37} Effective communication between physician and patient has been shown to reduce anxiety and uncertainty, enhancing patients' ability to recall prognosis and treatment options.³⁸

This study provides valuable insights into the perspectives of patients with chronic myeloid leukaemia and physicians regarding decisional needs. However, several limitations should be considered. Not all potential medication options were discussed with patients, possibly due to adherence to medication guidelines by physicians limiting patient exposure to certain medications. In addition, the retrospective design may introduce recall bias among patients and physicians. However, this design allowed us to understand personal experience and expand our knowledge on decisional needs. Moreover, selection bias may be present since participants were recruited through the Dutch CMyLife platform, which may have led to the inclusion of predominantly active and involved patients in our study. Nonetheless, including patients and physicians from multiple centres across the Netherlands may enhance the generalisability of findings to the broader population.

In conclusion, our findings are in line with wider literature and illustrate the complexity of decisional needs in CML management. These highlight the similarities, but also the gap between patient and physician perspectives on symptoms, quality of life and information needs. Addressing these gaps requires a patient-centred approach, emphasising SDM and tailoring

communication strategies to optimise patient outcomes and satisfaction. Future research should examine whether a well-designed decision aid with reliable information could improve patient-physician communication and empower patients with chronic myeloid leukaemia to have a more active role in the decision-making process.

Author affiliations

¹Research Institute for Oncology and Reproduction GROW, Maastricht University, Maastricht, Netherlands

²Department of Radiation Oncology MAASTRO, Maastricht University Medical Centre+, Maastricht, Netherlands

³Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University, Maastricht, Netherlands

⁴Department of Gastroenterology and Hepatology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands

⁵Department of Hematology, Radboud universitair medisch centrum, Nijmegen, Netherlands

⁶Department of Internal Medicine, Reinier de Graaf Groep, Delft, Netherlands

⁷Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

⁸CMyLife Program, A.T. TWINTEY, Eindhoven, Netherlands

⁹Department of Oncology, Rijnstate Hospital, Arnhem, Netherlands

Contributors YS, NB, RF and CK conceptualised the study. EW and CK collected the participants. MC and RF executed the study. MC, RF and CK collected the data. MC and SM prepared the data. MC, SM and RF analysed the data. MC drafted the manuscript. SM, YS, NB, EP, AD, RF, EW and CK reviewed and made revisions to the manuscript. SM is the guarantor.

Funding This project was made possible in part by Netherlands Organisation for Health Research and Development (ZonMw, grant 516022524), which included unrestricted educational grants from three pharmaceutical companies (AbbVie, AstraZeneca and Janssen Pharmaceutical Companies). Funding bodies had no role in the design of the study, collection and analysis of data or the decision to publish.

Competing interests YS, NB and EP declare research support from AbbVie, AstraZeneca and Janssen. All other authors declare no competing interests.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants, but ethical approval was waived before participants' recruitment by the Medical Ethical Committee METC Oost-Nederland; 2023-16198 exempted this study. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Since complete transcripts of interviews potentially allow for identification of individuals, complete transcripts cannot be provided.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Simone Mingels <https://orcid.org/0009-0000-9848-2391>

REFERENCES

- 1 Minciacchi VR, Kumar R, Krause DS. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. *Cells* 2021;10:117.
- 2 Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2020;18:1385–415.
- 3 Agrawal M, Garg RJ, Kantarjian H, et al. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the “best” therapy? *Curr Oncol Rep* 2010;12:302–13.
- 4 Santos FPS, Kantarjian H, Quintás-Cardama A, et al. Evolution of therapies for chronic myelogenous leukemia. *Cancer J* 2011;17:465–76.
- 5 Maas CCHM, van Klaveren D, Ector GICG, et al. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018. *Br J Haematol* 2022;196:1219–24.
- 6 Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. *Leukemia* 2011;25:201–10.
- 7 Cirmi S, El Abd A, Letinier L, et al. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). *Cancers (Basel)* 2020;12:826.
- 8 Held N, Atallah EL. Real-world Management of CML: Outcomes and Treatment Patterns. *Curr Hematol Malig Rep* 2023;18:167–75.
- 9 Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia* 2020;34:966–84.
- 10 Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017;28:iv41–51.
- 11 Lang F, Pemberton-Whiteley Z, Clements J, et al. P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING. *Hemasphere* 2023;7:e8318962.
- 12 Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. *Soc Sci Med* 1999;49:651–61.
- 13 Ernst J, Weissflog G, Brähler E, et al. Participation of haemato-oncological patients in medical decision making and their confidence in decisions. *Eur J Cancer Care (Engl)* 2011;20:534–8.
- 14 Reyna VF, Nelson WL, Han PK, et al. Decision making and cancer. *Am Psychol* 2015;70:105–18.
- 15 Spinnewijn L, Aarts J, Verschuur S, et al. Knowing what the patient wants: a hospital ethnography studying physician culture in shared decision making in the Netherlands. *BMJ Open* 2020;10:e032921.
- 16 Chewning B, Bylund CL, Shah B, et al. Patient preferences for shared decisions: a systematic review. *Patient Educ Couns* 2012;86:9–18.
- 17 O'Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med* 2014;89:1245–51.
- 18 Jacobsen M, O'Connor A, Stacey D. Decisional needs assessment in populations. 1999. Available: https://decisionaid.ohri.ca/docs/implement/Population_Needs.pdf
- 19 CMylife. Platform voor patiënten met hematologische ziekten, betrokkenen en zorgverleners, Available: <https://www.cmylife.nl>
- 20 Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? *Qual Res Psychol* 2021;18:328–52.
- 21 NLQF NC. Referencing the dutch qualifications framework nlqf to the european qualifications framework: update september 2019 final version. 2019.
- 22 Hematologie NVv. Richtlijn Chronische Myeloïde Leukemie, 2023. Available: <https://publicatie.hematologienederland.nl/richtlijnen/chronische-myeloïde-leukemie-2>
- 23 Renzi C, Riva S, Masiero M, et al. The choice dilemma in chronic hematological conditions: Why choosing is not only a medical issue? A psycho-cognitive perspective. *Crit Rev Oncol Hematol* 2016;99:134–40.
- 24 Efficace F, Rosti G, Aaronson N, et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. *Haematologica* 2014;99:788–93.
- 25 Loh KP, Tsang M, LeBlanc TW, et al. Decisional involvement and information preferences of patients with hematologic malignancies. *Blood Adv* 2020;4:5492–500.
- 26 Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. *Br J Cancer* 2012;107:904–9.
- 27 Coleman M. Patient empowerment in the management of chronic myeloid leukemia. *Clin J Oncol Nurs* 2014;18:E12–8.
- 28 Medlock S, Eslami S, Askari M, et al. Health information-seeking behavior of seniors who use the Internet: a survey. *J Med Internet Res* 2015;17:e10.
- 29 Clements J, Fleischman A, Lerner V, et al. The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist. *Future Oncol* 2023;19:1197–208.
- 30 Ector G, Verweij L, Hermens R, et al. Filling the gaps of patient information needs and information perception in chronic myeloid leukemia with the patient-physician co-produced web-based platform CMylife. *Patient Educ Couns* 2022;105:686–94.
- 31 Hall A, Lynagh M, Bryant J, et al. Supportive care needs of hematological cancer survivors: a critical review of the literature. *Crit Rev Oncol Hematol* 2013;88:102–16.
- 32 Berry DC, Knapp PR, Raynor T. Is 15 per cent very common? Informing people about the risks of medication side effects. *Int J Pharm Pract* 2011;10:145–51.
- 33 Tran Y, Lamprell K, Nic Giolla Easpaig B, et al. What information do patients want across their cancer journeys? A network analysis of cancer patients' information needs. *Cancer Med* 2019;8:155–64.
- 34 Graffigna G, Cecchini I, Breccia M, et al. Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine. *Qual Life Res* 2017;26:2739–54.
- 35 Jansen J, Butow PN, van Weert JCM, et al. Does age really matter? Recall of information presented to newly referred patients with cancer. *J Clin Oncol* 2008;26:5450–7.
- 36 Kessels RPC. Patients' memory for medical information. *J R Soc Med* 2003;96:219–22.
- 37 Nguyen MH, Smets EMA, Bol N, et al. Fear and forget: how anxiety impacts information recall in newly diagnosed cancer patients visiting a fast-track clinic. *Acta Oncol* 2019;58:182–8.
- 38 van Osch M, Sep M, van Vliet LM, et al. Reducing patients' anxiety and uncertainty, and improving recall in bad news consultations. *Health Psychol* 2014;33:1382–90.